Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde
By, Admin1 min read
Share
At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS)
The safety profile was consistent with previously reported studies of Onivyde
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
